ClinicalTrials.gg

Program

CVL006

A development code. Also written as “CVL006 in combination with 9MW2821”, “CVL006 combined with pemetrexed and carboplatin” and “CVL006 in combination with SKB264”.

Its studies are led by Convalife (Shanghai).

Furthest: phase 2, since Aug 22, 20253 company-led studies, 3 open or runningNext primary completion: May 20, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Convalife (Shanghai)33 open or runningphase 2since Aug 22, 2025Sep 20, 2024May 20, 2028phase 1 · NCT06621615

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06621615 · 120 planned
  2. Aug 22, 2025Phase 2 study in Advanced Solid TumorNCT07157956 · 318 planned · China
  3. May 6, 2026Phase 2 study in Advanced Solid TumorNCT07615660 · 108 planned

Ahead

  1. May 20, 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06621615
  2. Aug 12, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07157956
  3. Apr 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07615660

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07615660Advanced Solid Tumor2Not yet recruitingApr 30, 2029108
NCT07157956Advanced Solid Tumor · China2Not yet recruitingAug 12, 2028318
NCT06621615Advanced Solid Tumor1Not yet recruitingMay 20, 2028120

How it is read

Names in the registry

  • “CVL006 in combination with 9MW2821”, 2 entries
  • “CVL006 combined with pemetrexed and carboplatin”, 1 entry
  • “CVL006 in combination with SKB264”, 1 entry
  • “CVL006 in combination with DS-8201”, 1 entry
  • “CVL006 in combination with Enfortumab Vedotin”, 1 entry

Codes read as this program: CVL006.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.